ImmunityBio, Inc. — Director's Dealing 2021

May 6, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ImmunityBio, Inc. (IBRX)
CIK: 0001326110
Period of Report: 2021-05-03

Reporting Person: Selecky Christobel (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-05-03	Stock Option (right to buy)	$17.24	A	21873	Acquired	2031-05-03	Common Stock (21873)	Direct

Footnotes

F1: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through such applicable vesting date, the shares subject to the award will vest in three (3) equal installments on each of March 9, 2022, March 9, 2023 and March 9, 2024, such that the award will be fully vested March 9, 2024.